Canada Markets closed

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.1700+0.1000 (+3.26%)
At close: 04:00PM EDT
3.1700 0.00 (0.00%)
After hours: 05:19PM EDT
Full screen
Loading interactive chart...
  • Business Wire

    Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., September 06, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 12:55 pm ET.

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.

  • Business Wire

    Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene e